Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $44 | $38 | $36 | $24 |
| G&A Expenses | $15 | $14 | $12 | $5 |
| SG&A Expenses | $15 | $14 | $12 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $59 | $51 | $48 | $29 |
| Operating Income | -$71 | -$51 | -$48 | -$29 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | -$0 | $1 | $1 |
| Pre-Tax Income | -$70 | -$51 | -$48 | -$28 |
| Tax Expense | -$1 | $0 | $0 | $0 |
| Net Income | -$69 | -$51 | -$48 | -$29 |
| % Margin | – | – | – | – |
| EPS | -2.16 | -1.76 | -2.74 | -4.86 |
| % Growth | -22.7% | 35.8% | 43.6% | – |
| EPS Diluted | -2.16 | -1.76 | -2.74 | -4.86 |
| Weighted Avg Shares Out | 32 | 29 | 17 | 6 |
| Weighted Avg Shares Out Dil | 32 | 29 | 17 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $13 | $1 | $1 | $1 |
| EBITDA | -$58 | -$51 | -$46 | -$27 |
| % Margin | – | – | – | – |